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Abstract
Context: In March 2003, the French Ministry of Health implemented a program on preparedness and response to a
biological attack using smallpox as weapon. This program included the establishment of a preoutbreak national team that
could be revaccinated against smallpox.
Objective: To identify demographic and clinical factors associated with vaccination success defined as the presence of a
pustule at the inoculation site at day 8 (days 7–9), with an undiluted vaccinia virus derived from a Lister strain among
preimmunized volunteers.
Volunteers and Methods: From March 2003 to November 2006, we have studied prospectively 226 eligible volunteers.
Demographic data were recorded for each volunteer (age, sex, number of previously smallpox vaccinations and date of the
last vaccination). Smallpox vaccine adverse reactions were diagnosed on the basis of clinical examination performed at days
0, 7, 14, 21 and 28 after revaccination.
Results: A total of 226 volunteers (sex ratio H/F=2.7) were revaccinated. Median age was 45 years (range: 27–63 yrs). All
volunteers completed follow-up. Median number of vaccinations before revaccination was 2 (range: 1–8). The median delay
between time of the study and the last vaccination was 29 years (range; 18–60 yrs). Sixty-one volunteers (27%) experienced
one (n=40) or more (n=21) minor side effects during the 2–14 days after revaccination. Successful vaccination was noted
in 216/226 volunteers (95.6%) at day 8 and the median of the pustule diameter was 5 mm (range: 1–20 mm). Size of the
pustule at day 8 was correlated with age (p=0.03) and with the presence of axillary adenopathy after revaccination
(p=0.007). Sex, number of prior vaccinations, delay between the last vaccination and revaccination, and local or systemic
side effects with the exception of axillary adenopathy, were not correlated with the size of the pustule at day 8.
Conclusions: Previously vaccinated volunteers can be successfully revaccinated with the Lister strain.
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Introduction
The events of 2001 in the United States had worldwide
repercussions on the awareness of bioterrorism as well as on the
development of plans to counteract bioterrorism amongst many
countries. Governments and international entities with responsi-
bilities related to maintenance of peace, security, safety and health
protection reviewed urgently their political, economic, diplomatic,
military and legal means to face up to such attacks and embarked
upon major efforts to increase their preparedness. Individual
nation states have developed plans to fight against bioterrorism
and have united in order to resist this threat. More than 150
pathogens have been reported as potential agents for bioterrorism
[1]. Among them, smallpox represents a high threat [2–4]. It was
declared eradicated worldwide by the World Health Organisation
in 1979 following a smallpox-eradication campaign begun in 1958
and intensified in 1967, and the last case of endemic smallpox
occurred in Somalia in 1977 [5]. Throughout world, vaccination
against smallpox has been discontinued since about 1982. In
France, routine childhood immunization using the Lister strain
ceased in 1979, and reimmunization of healthcare workers in 1984
[6]. This means, that a large population is susceptible, and any
PLoS ONE | www.plosone.org 1 December 2008 | Volume 3 | Issue 12 | e4087new case of smallpox would have to be the result of human
accidental or deliberate release, could be associated to a major
epidemic.
In March 2003, the French Ministry of Health implemented a
program on preparedness and response to a biological attack using
smallpox as weapon [7]. This program included the establishment
of a preoutbreak national team that could be revaccinated against
smallpox and can be called upon to investigate and manage initial
suspected or confirmed cases of smallpox in France. People, who
were selected to this team, were eligible volunteers, had received at
least one dose of smallpox vaccine in the past and have no
contraindication to a reimminization. This program used the
Lister strain (PourquierH vaccine) which received French Health
Products Safety Agency (AFSSAPS) licensure for this exclusive
purpose.
The objective of this study was to identify demographic and
clinical factors associated with vaccination success, defined as the
presence of a pustule at the inoculation site eight days post
vaccination and measured by the size of the pustule among 226
eligible preimmunized volunteers.
Methods
From March 2003 to November 2006, we have studied
prospectively 226 eligible volunteers selected for the French
national team against smallpox. They have received at least one
dose of smallpox vaccine in the past, without major side effects,
and have evidence of vaccine ‘‘take’’ as evidenced by the presence
of a scar resulting from previous smallpox vaccination or
notification on a notebook vaccination. Reimmunization for this
team was performed with the Lister strain (PourquierH vaccine).
Screening to identify and exclude subjects with contraindications
for them or household close contacts to smallpox immunization
was performed (table 1). An HIV test was performed two weeks
before vaccination. A urine pregnancy test on the day scheduled
for vaccination was also performed for women of childbearing age.
Written informed consent was obtained from all volunteers.
French Health Products Safety Agency (AFSSAPS) approved this
study.
There is currently two licensed smallpox vaccine in France
using the Lister strain. There are approximately 72 millions doses
of vaccine potentially available. The vaccine used (PourquierH
vaccine) contains live unattenuated vaccinia virus derived from the
Lister strain which produces cross immunity against variola major
and minor. The titer of vaccinia virus was 10
7.7 pfu/mL. This
lyophilized vaccine, product prepared from calf lymph, was
reconstituted by adding sterile diluent to the powder and
administered into the dermis by using the multiple-puncture
technique with a presterilized bifurcated needle (10–15 punctures
in an area of about 5 mm in diameter as recommended for
revaccination over the insertion of the left deltoid muscle). The
same physician performed all the vaccinations to exclude technical
problems associated with the vaccination procedure. The
vaccination site was covered with gauze in combination with a
semipermeable membrane. Dressings were changed and the
vaccination sites were assessed every seven days (d0–d28) until
the lesions dried and an eschar formed. Following revaccination,
vaccination success was measured by the development of a
vaccination site take, defined as the presence of a pustule at the
inoculation site 7 to 9 days post vaccination.
Demographic data were recorded for each volunteer (age, sex,
number of previously smallpox vaccinations and date of the last
vaccination). There were no restrictions on work activities
following revaccination. Smallpox vaccine adverse reactions were
diagnosed on the basis of clinical examination performed at days
0, 7, 14, 21 and 28 after revaccination. Volunteers were also
questioned at each follow-up visit for the presence of any vaccine-
related adverse events such as local and systemic symptoms for at
least 4 weeks after revaccination. Fever was defined as temperature
$37.8uC.
The quantitative variables (i.e.: age, size of the pustule, delay
between the vaccination and the revaccination) are not normally
distributed. By consequence, the non parametric tests using exact
calculation rather than asymptotic ones have been applied by
using StatXactH software version 6 (Cytel Studio). Without any
certitude regarding the hypothetic direction of the relation, all tests
have been interpreted based on a two-tails p-value. The a risk has
been chosen at 5%. The Bonferoni correction has been taken into
account according to the number of tests done. The quantitative
variables have been crossed by using the Mann-Whitney exact test.
The Spearman rank correlation test has been used to test the
correlation between quantitative variables.
Results
A total of 226 volunteers (sex ration H/F=2.70) were
revaccinated and included in this study (table 2). Median age of
the cohort was 45 years (range: 27–63 years). All volunteers
completed follow-up. All volunteers have been vaccinated against
smallpox for the first time before one year old. Median number of
vaccinations before revaccination was 2 (range: 1–8). Among
volunteers, 45 (19.9%) received only one vaccination in the past.
Table 1. Contraindications against vaccination for volunteers and household contacts (7).
N History or presence of eczema or atopic dermatitis
N Other active acute, chronic or exfoliative skin conditions that disrupt the epidermis
N Conditions associated with immunosuppression (cancer, HIV, chemotherapy, radiotherapy, transplantation, autoimmune conditions, immunosuppressive
medications…)
N Pregnancy, desire to become pregnant in the month following the revaccination or breastfeeding
N Having children ,1 year
N Allergy to any component of the vaccine (polymyxin B, streptomycin, tetracycline or neomycin)
N Neurological disease
N Taking ocular steroid medication
N Heart disease
N Fever within 8 days before revaccination
doi:10.1371/journal.pone.0004087.t001
Smallpox Vaccine
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vaccination was 29 years (range: 18–60 years).
Among the 226 volunteers, 61 (27%) experienced one (n=40)
or more (n=21) minor side effects during the 2–14 days after
revaccination. No side effect was reported during the third and the
fourth week after revaccination. No serious adverse effect was
notified and no adverse event was reported in their household
close contacts. Moreover, no cardiac complication following
revaccination was reported in this study. Local symptoms were:
local pruritis (n=17) (8%), axillary lymphadenopathy (n=7) (3%),
and large vaccination reaction (robust take) .7.5 cm in diameter
(n=2) (1%), and systemic symptoms were: fever .37.8uC (n=27)
(12%), fatigue (n=14) (6%), headache (n=6) (3%), myalgia (n=6)
(3%), nausea (n=2) (1%), diarrhea (n=2) (1%) and cough (n=2)
(1%) (Table 3).
Successful vaccination was noted in 216/226 volunteers (95.6%) at
day 8 (days 7–9). Median of the pustule diameter in these 216
volunteers, at day 8 after revaccination was 5 mm (range: 1–22 mm):
median age was 45.5 years (range: 27–63 years) and median delay
between time of the study and the last vaccination was 29 years
(range: 18–60 years). Among volunteers, 10 did not develop any
clinical take (pustule diameter=0) at the vaccination site (median age
was 41 years (range: 33–49 years) and median delay between time of
the study and the last vaccination was 33.5 years (range: 20–
45 years)). We did not find any difference between these two groups
of volunteers with or without pustule.
A larger size of the pustule at day 8 was statistically correlated with
a greater age (p=0.03) and with the presence of axillary adenopathy
after revaccination (p=0.007). Sex, number of prior vaccinations,
delay between the last vaccination and revaccination, and local or
systemic side effects with the exception of axillary adenopathy, were
not associated with the size of the pustule at day 8.
Discussion
The data of this study shows that volunteers previously
immunized with smallpox vaccine are successfully revaccinated
with an undiluted Lister strain.
Successful vaccination was noted in 216 of the 226 volunteers
(95.6%). This result is in accordance with other studies which used
an undiluted Lister strain [8,9]. Size of the pustule was
significantly correlated with age and presence of axillary
adenopathy after revaccination. As reported in another study,
sex, number of prior immunizations and delay between the last
vaccination and revaccination were not correlated with the size of
the pustule at day 8 [10].
It has been usually reported that compared with vaccinia-naı ¨ve
subjects, prevaccinated patients had significantly smaller pustule
lesion [11]. The fact that a larger size of the pustule was
statistically correlated in our study with a greater age, suggests that
some older prevaccinated volunteers are similar to vaccinia-naı ¨ve
individuals who do not have any immunity to smallpox. This can
be due to loss of immune function with aging. However, this loss of
immune function, is not correlated with number of prior
immunizations and delay between the last vaccination and
revaccination: both CD4+ and CD8+ cells specific for vaccinia
virus have been found to persist for up to 75 years after the last
immunization [12–14]. Moreover, persistence of humoral immu-
nity to smallpox has been reported in patients up to 60 years after
the last immunization [15].
In the literature, local lymphadenopathy is reported in 7 to 88%
of cases [16]. But usually, and whatever the vaccine used, it has
been reported that more naive subjects presented regional
lymphadenopathy than non-naive subjects [17,18]. This could
be the fact that vaccinia-naı ¨ve volunteers shed virus from the
vaccination site 2 to 6 days longer and had significantly higher
peak mean viral titers when compared with prevaccinated
volunteers [8,11].
It has been also reported that the 1:5 and 1:10 dilutions of
smallpox vaccine in adults who had not been previously
immunized, were associated with a smaller incidence of adenop-
athy than those reported in naı ¨ve subjects given undiluted vaccine
[19,20]. This is in accordance with our findings, suggesting that
volunteers who have a larger pustule due to an increased local
inflammation have an increase incidence of regional lymphade-
nopathy.
In our study, only 61 patients (27%) experienced at least one
minor side effect during the 2–14 days after revaccination with the
Lister strain. These side effects included only moderate local and/or
systemic adverse events. No serious adverse effect, such as
postvaccinal encephalitis, progressive vaccinia, eczema vaccinatum,
generalized vaccinia, inadvertent inoculation, cardiac complication
or death was notified in the volunteers and their household close
contacts [21–25]. Local and systemic symptoms are quite common
with this live viral vaccine, consistent with the presence of an acute
viral illness. However, with the exception of fever, all the symptoms
observed in our study were less frequent than those reported in
vaccinia naı ¨ve volunteers vaccinated with a lyophilized form
(Dryvax, Wyeth Laboratories, Marietta, Pa.) and a frozen
preparation (Aventis Pasteur, Swift-water, Pa.), live-virus vaccines,
both derived from the New York City Board of Health vaccinia
strain, even at diluted doses [17,19,20,26]. However, frequency of
Table 2. Characteristics of the volunteers before
revaccination.
Characteristics Results
Number of volunteers 226
Sex ratio (M/F) 2.7 (165/61)
Median age (range) yr 45 (27–63)
Median number of prior vaccination (range) 2 (1–8)
Median delay between the last vaccination yr (range) 29 (18–60)
doi:10.1371/journal.pone.0004087.t002
Table 3. Local and systemic symptoms among the 226
volunteers after the revaccination*.
Adverse events n (%)
fever .37.8uC2 7 ( 1 2 )
Fatigue 14 (6)
local pruritis 17 (8)
axillary lymphadenopathy 7 (3)
headache 6 (3)
myalgia 6 (3)
nausea 2 (1)
diarrhea 2 (1)
cough 2 (1)
large vaccination reaction (diameter .7.5 cm)** 2 (1)
*61 volunteers (27%) experienced one (n=40) or more (n=21) side effects.
**ref (30).
doi:10.1371/journal.pone.0004087.t003
Smallpox Vaccine
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volunteers inotherstudies,includingthe Listerstrain[8,17–19].The
fact that fewer adverse reactions are observed in non-naı ¨ve patients
when compared with events in vaccinia-naı ¨ve participants are
probably due to immunologic memory. This hypothesis is
supported by the differences between previously vaccinated subjects
and vaccinia-naı ¨ve subjects in local and systemic symptoms and
signs and the quantify of viral shedding [8].
Previously vaccinated volunteers can be successfully revaccinat-
ed with the Lister strain. Large studies are needed to analyse
second and third generations vaccines [27–29].
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